The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Cefepime Hydrochloride
Cefepime Hydrochloride · CEFEPIME HYDROCHLORIDE 2 g/1 · Injection, Powder, For Solution · Intravenous · Hikma Pharmaceuticals USA Inc.
NDC 00143-9383-10 · 10 VIAL in 1 CARTON / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$50.00
Reported to Texas DSHS · 2026 annual filing · Hikma Pharmaceuticals USA Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 500 MG
$1.296
HCPCS J0692 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$1,478
49 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA214402
- TE code
- AP
- Approval date
- May 22, 2024
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Cefepime Hydrochloride (Injection, Powder, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Sagent Pharmaceuticals | CEFEPIME HYDROCHLORIDE 1 g/20mL | Sep 3, 2026 | Sep 3, 2026 |
| Sagent Pharmaceuticals | CEFEPIME HYDROCHLORIDE 2 g/20mL | Sep 3, 2026 | Sep 3, 2026 |
| Qilu Pharmaceutical Co., Ltd. | CEFEPIME HYDROCHLORIDE 1 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Qilu Pharmaceutical Co., Ltd. | CEFEPIME HYDROCHLORIDE 2 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Qilu Pharmaceutical Co., Ltd. | CEFEPIME HYDROCHLORIDE 500 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | CEFEPIME HYDROCHLORIDE 1 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | CEFEPIME HYDROCHLORIDE 2 g/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hikma Pharmaceuticals USA Inc. | CEFEPIME HYDROCHLORIDE 2 g/1 | Jul 15, 2026 | Aug 31, 2026 |
| Hikma Pharmaceuticals USA Inc. | CEFEPIME HYDROCHLORIDE 1 g/1 | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Cefepime Hydrochloride — NDC 00143-9383-10," retrieved September 3, 2026, https://drugdashboards.com/drug/00143938310.
Free to cite with attribution — see how the data is put together.